User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

References

• Abramson, H. A. (1967). The Second International Conference on the Use of LSD in Psychotherapy. New York: Bobbs-Merrill Co.
   Google Scholar
• Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293–300.
   PubMed Web of Science ®Google Scholar
• Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. A., & Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs, 40(3), 225–236.
   PubMed Web of Science ®Google Scholar
• Busch, A. K., & Johnson, W. C. (1950). LSD 25 as an aid in psychotherapy; preliminary report of a new drug. Diseases of the Nervous System, 11(8), 241–243.
   PubMedGoogle Scholar
• Cohen, S., & Ditman, K. S. (1962). Complications associated with lysergic acid diethylamide (LSD-25). Journal of the American Medical Association, 181, 161–182.
   PubMed Web of Science ®Google Scholar
• Croxford, J. L. (2003). Therapeutic potential of cannabinoids in CNS disease. CNS Drugs, 17(3), 179–202.
   Google Scholar
• Deakin, J. F., Lees, J., McKie, S., Hallak, J. E., Williams, S. R., & Dursun, S. M. (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry, 65(2), 154–164.
   PubMed Web of Science ®Google Scholar
• Doblin, R. (2002). A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. Journal of Psychoactive Drugs, 34(2), 185–194.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Bigelow, G. E., & Henningfield, J. E. (1980). Similarities in animal and human drug-taking behaviour. Advances in Substance Abuse, 1, 1–90.
   Google Scholar
• Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berlin), 187(3), 268–83; discussion 284–292.
   PubMed Web of Science ®Google Scholar
• Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol, 22, 621–32.
   PubMed Web of Science ®Google Scholar
• Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic Drugs Reconsidered. New York: Basic Books.
   Google Scholar
• Grof, S. (1975). Realms of the Human Unconscious. Observations From LSD Research. London. Souvenir Press.
   Google Scholar
• Halpern, J. H., & Pope, H. G., Jr (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119.
   PubMed Web of Science ®Google Scholar
• Iversen, L. (2003). Cannabis and the brain. Brain, 126(6), 1252–1270.
   PubMed Web of Science ®Google Scholar
• Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620.
   PubMed Web of Science ®Google Scholar
• Lancet Editorial (2006). Reviving research into psychedelic drugs. Lancet, 367(9518), 1214.
   Google Scholar
• Liebrenz, M., Borgeat, A., Leisinger, R., & Stohler, R. (2007). Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly, 137(15–16), 234–236.
   Google Scholar
• Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: a review of the program of research. Journal of Psychoactive Drugs, 30(4), 381–418.
   PubMed Web of Science ®Google Scholar
• McKeganey, N. (2009). The classification of ecstasy is not a black-and-white issue. Retrieved January 15, 2009, from www.guardian.co.uk.
   Google Scholar
• Mithoefer, M., Mithoefer, A., & Wagner, M. (2008). Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in subjects with chronic posttraumatic stress disorder: A Phase II clinical trial completed 19 September, 2008. Poster presented at the 24th Annual Meeting of the International Society of Traumatic Stress Studies, Chicago.
   Google Scholar
• Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740.
   PubMed Web of Science ®Google Scholar
• Morgan, C. J. A., Muettzelfeldt, L., & Curran, H. V. (2008). Reclassifying psychoactive substances on the basis of their actual harms: an internet survey of drug users [Abstract]. Journal of Psychopharmacology, 22(5), S05.
   Google Scholar
• Murphy, P. N. (2007). Assessing drug-related harm. Lancet, 369(9576), 1856.
   Google Scholar
• Nutt, D. J. (2009). Equasy—an overlooked addiction with implications for the current debate on drug harms. Journal of Psychopharmacology, 23(1), 3–5.
   PubMed Web of Science ®Google Scholar
• Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 369(9566), 1047–1053.
   PubMed Web of Science ®Google Scholar
• Sandison, R. A. (1954). Psychological aspects of the LSD treatment of the neuroses. Journal of Mental Science, 100(419), 508–515.
   PubMed Web of Science ®Google Scholar
• Selvaraj, S., Hoshi, R., Bhagwagar, Z., Murthy, N. V., Hinz, R., Cowen, P., Curran, H. V., & Grasby, P. (2009). Brain serotonin transporter binding in former users of MDMA (‘ecstasy’). British Journal of Psychiatry, 194(4), 355–359.
   PubMed Web of Science ®Google Scholar
• Sessa, B. (2005). Can psychedelics have a role in psychiatry once again? British Journal of Psychiatry, 186, 457–458.
   PubMed Web of Science ®Google Scholar
• Sessa, B., & Nutt, D. J. (2007). MDMA, politics and medical research: have we thrown the baby out with the bathwater? Journal of Psychopharmacology, 21(8), 787–791.
   PubMed Web of Science ®Google Scholar
• Sewell, R. A., Halpern, J. H., & Pope, H. G., Jr (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920–1922.
   PubMed Web of Science ®Google Scholar
• Zarate, C. A., Jr, Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864.
   PubMed Web of Science ®Google Scholar